Skip to main content

Drug Interactions between probenecid and tazobactam

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

probenecid tazobactam

Applies to: probenecid and tazobactam

MONITOR: Coadministration with probenecid may increase and prolong the serum concentrations of tazobactam. The mechanism is competitive inhibition by probenecid of the renal tubular secretion of tazobactam via OAT1 and OAT3. A one gram oral dose of probenecid reduced the clearance of tazobactam (administered by injection in combination with piperacillin) by approximately 20% to 25% and prolonged its half-life by 71%. The peak plasma concentration was not affected.

MANAGEMENT: Although the clinical relevance of this interaction has not been established, caution may be advisable when probenecid must be used with tazobactam-containing preparations. The product labeling for piperacillin-tazobactam recommends avoiding concomitant use with probenecid unless the benefit outweighs the risk.

References

  1. (2001) "Product Information. Zosyn (piperacillin-tazobactam)." Lederle Laboratories
  2. (2015) "Product Information. Zerbaxa (ceftolozane-tazobactam)." Cubist Pharmaceuticals Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer